白细胞介素-38作为心力衰竭的潜在诊断生物标志物。

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-02-01 Epub Date: 2025-02-13 DOI:10.1080/17520363.2025.2459595

Hongman Liu, Mingliang Zhang, Wen Gong, Faqiang Tian, Lei Zhang, Jin Zhao, Bing Xiang, Jie Hui

{"title":"白细胞介素-38作为心力衰竭的潜在诊断生物标志物。","authors":"Hongman Liu, Mingliang Zhang, Wen Gong, Faqiang Tian, Lei Zhang, Jin Zhao, Bing Xiang, Jie Hui","doi":"10.1080/17520363.2025.2459595","DOIUrl":null,"url":null,"abstract":"Objective: Interleukin-38 (IL-38) attenuates inflammation, myocardial injury, and ventricular remodeling after myocardial infarction, which potentially reduces the incidence of heart failure (HF). This study aimed to evaluate the diagnostic value of IL-38 for HF.Methods: IL-38 was detected via enzyme-linked immunosorbent assay in the serum samples of 238 hF patients and 30 healthy controls when enrollment.Results: IL-38 was elevated in HF patients compared with controls (p = 0.002). Receiver operating characteristic (ROC) analysis showed that the area under the curve (AUC) of IL-38 for predicting HF risk was 0.676 (95% confidence interval = 0.594-0.758). The Youden index of IL-38 for diagnosing HF peaked at 0.329 when the cutoff value of IL-38 was set as 6 ng/mL, with sensitivity and specificity of 0.833 and 0.496, respectively. Before (odds ratio = 1.493, p = 0.002) and after (odds ratio = 1.500, p = 0.007) adjustment of age and gender by multivariable regression analysis, IL-38 was associated with a higher HF risk. Moreover, the combination of IL-38 with age and gender possessed a good value for predicting HF risk (AUC = 0.796, 95% confidence interval = 0.706-0.885).Conclusion: IL-38 is increased in HF patients compared with controls, and its combination with age and gender shows a good value for the diagnosis of HF.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"105-111"},"PeriodicalIF":1.9000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834501/pdf/","citationCount":"0","resultStr":"{\"title\":\"Interleukin-38 as a potential diagnostic biomarker for heart failure.\",\"authors\":\"Hongman Liu, Mingliang Zhang, Wen Gong, Faqiang Tian, Lei Zhang, Jin Zhao, Bing Xiang, Jie Hui\",\"doi\":\"10.1080/17520363.2025.2459595\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: Interleukin-38 (IL-38) attenuates inflammation, myocardial injury, and ventricular remodeling after myocardial infarction, which potentially reduces the incidence of heart failure (HF). This study aimed to evaluate the diagnostic value of IL-38 for HF.Methods: IL-38 was detected via enzyme-linked immunosorbent assay in the serum samples of 238 hF patients and 30 healthy controls when enrollment.Results: IL-38 was elevated in HF patients compared with controls (p = 0.002). Receiver operating characteristic (ROC) analysis showed that the area under the curve (AUC) of IL-38 for predicting HF risk was 0.676 (95% confidence interval = 0.594-0.758). The Youden index of IL-38 for diagnosing HF peaked at 0.329 when the cutoff value of IL-38 was set as 6 ng/mL, with sensitivity and specificity of 0.833 and 0.496, respectively. Before (odds ratio = 1.493, p = 0.002) and after (odds ratio = 1.500, p = 0.007) adjustment of age and gender by multivariable regression analysis, IL-38 was associated with a higher HF risk. Moreover, the combination of IL-38 with age and gender possessed a good value for predicting HF risk (AUC = 0.796, 95% confidence interval = 0.706-0.885).Conclusion: IL-38 is increased in HF patients compared with controls, and its combination with age and gender shows a good value for the diagnosis of HF.\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\" \",\"pages\":\"105-111\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834501/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2025.2459595\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2459595","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

目的：白细胞介素-38 （IL-38）可减轻心肌梗死后的炎症、心肌损伤和心室重构，从而可能降低心力衰竭（HF）的发生率。本研究旨在评价IL-38对心衰的诊断价值。方法：采用酶联免疫吸附法检测238例hF患者和30例健康对照者血清中IL-38的含量。结果：与对照组相比，HF患者IL-38水平升高（p = 0.002）。受试者工作特征（ROC）分析显示，IL-38预测HF风险的曲线下面积（AUC）为0.676（95%可信区间= 0.594-0.758）。当IL-38临界值为6 ng/mL时，IL-38诊断HF的约登指数最高为0.329，敏感性为0.833，特异性为0.496。多变量回归分析调整年龄和性别前（优势比= 1.493,p = 0.002）和调整年龄和性别后（优势比= 1.500,p = 0.007）， IL-38与较高的HF风险相关。IL-38与年龄、性别联合预测HF风险具有较好的预测价值（AUC = 0.796, 95%可信区间= 0.706 ~ 0.885）。结论：与对照组相比，HF患者IL-38水平升高，且IL-38与年龄、性别的结合对HF的诊断有较好的价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Interleukin-38 as a potential diagnostic biomarker for heart failure.

Objective: Interleukin-38 (IL-38) attenuates inflammation, myocardial injury, and ventricular remodeling after myocardial infarction, which potentially reduces the incidence of heart failure (HF). This study aimed to evaluate the diagnostic value of IL-38 for HF.

Methods: IL-38 was detected via enzyme-linked immunosorbent assay in the serum samples of 238 hF patients and 30 healthy controls when enrollment.

Results: IL-38 was elevated in HF patients compared with controls (p = 0.002). Receiver operating characteristic (ROC) analysis showed that the area under the curve (AUC) of IL-38 for predicting HF risk was 0.676 (95% confidence interval = 0.594-0.758). The Youden index of IL-38 for diagnosing HF peaked at 0.329 when the cutoff value of IL-38 was set as 6 ng/mL, with sensitivity and specificity of 0.833 and 0.496, respectively. Before (odds ratio = 1.493, p = 0.002) and after (odds ratio = 1.500, p = 0.007) adjustment of age and gender by multivariable regression analysis, IL-38 was associated with a higher HF risk. Moreover, the combination of IL-38 with age and gender possessed a good value for predicting HF risk (AUC = 0.796, 95% confidence interval = 0.706-0.885).

Conclusion: IL-38 is increased in HF patients compared with controls, and its combination with age and gender shows a good value for the diagnosis of HF.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.